Addressing the Unmet Need in Nonalcoholic Steatohepatitis

NAFLDHepatic Manifestation of Metabolic

Syndromea

NAFLD (cont)Hepatic Manifestation of Metabolic

Syndromea

NAFLD/NASH Closely Associated With Visceral Obesity, Insulin

Resistance

AASLDCurrent Therapeutic Recommendations for

NAFLD/NASH

Pioglitazone vs PlaceboSignificant Improvement of Histologic Features

and Insulin Sensitivity

11β-HSD1 Inhibitor RO5093151 Inhibits Adipocyte Differentiation

Galectin-3 Binding Drug GR-MD-02 Inhibits Hepatic Injury in Mouse

Model

Obeticholic Acid Improves Insulin Sensitivity and Markers of Liver

Injury

Selective Serotonin 2C Receptor Agonists Aid Weight Loss

Phentermine and Topiramate ER, an STR, Improves Weight Loss

Incretin Mimetics and Analogs Aid Maintenance of Glucose Balance

Abbreviations

References

References (cont)

References (cont)